Showing 1-10 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Collaboration for Global T1D Care | Acora | Rebecca Goldman | Mission | 01-December-2025 to 31-January-2027 | $738.500,00 |
| Telemedicine-Delivered Cognitive Behavioral Therapy to Reduce Diabetes Distress in Young Adults with Type 1 Diabetes (CBT-DD) | Albert Einstein College of Medicine | Jeffrey Gonzalez | Improving Lives | 01-September-2021 to 30-June-2027 | $1.870.600,00 |
| Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults with Type 1 Diabetes | Albert Einstein College of Medicine | Jeffrey Gonzalez | Improving Lives | 01-December-2022 to 30-November-2026 | $1.672.180,00 |
| Stromal Cell Targeted Tolerogenic mRNA Therapy for T1D | Endotope Biosciences | Raymond Liang | Cures | 15-December-2025 to 14-December-2027 | $550.417,82 |
| Defining antigen-presenting cell – CD8 T cell crosstalk in type 1 diabetes using uLIPSTIC | Icahn School of Medicine at Mount Sinai | Verena van der Heide | Cures | 01-May-2026 to 30-April-2029 | $600.000,00 |
| Cardiotoxic Circulating Extracellular Vesicles: New Drivers of Type 1 Diabetes-induced Cardiomyopathy | Icahn School of Medicine at Mount Sinai | Susmita Sahoo | Improving Lives | 01-April-2025 to 30-September-2026 | $199.998,24 |
| Protective Genetic and Pharmacological Interventions to Prevent Cytokine and Autoimmune-based Destruction of β cells. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-April-2025 to 31-March-2027 | $559.996,54 |
| Protective Interventions against Loss of Function and Destruction of β cells in Type 1 Diabetes. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-March-2026 to 28-February-2031 | $999.999,00 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 31-December-2026 | $305.000,00 |
| Targeting pathogenic Th17 cells as shared mechanisms in MS, SLE and T1D | Icahn School of Medicine at Mount Sinai | Ka Lung Cheung | Cures | 01-September-2026 to 31-August-2027 | $149.950,03 |